Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.
Zhang J, Bodenko V, Larkina M, Bezverkhniaia E, Xu T, Liao Y, Abouzayed A, Plotnikov E, Tretyakova M, Yuldasheva F, Belousov MV, Orlova A, Tolmachev V, Gräslund T, Vorobyeva A.
Zhang J, et al.
J Control Release. 2024 May 8;370:468-478. doi: 10.1016/j.jconrel.2024.04.051. Online ahead of print.
J Control Release. 2024.
PMID: 38697314
Free article.